Humacyte, Inc. $HUMA Shares Bought by LJI Wealth Management LLC

LJI Wealth Management LLC boosted its stake in shares of Humacyte, Inc. (NASDAQ:HUMA) by 27.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 288,000 shares of the company’s stock after acquiring an additional 62,000 shares during the quarter. LJI Wealth Management LLC owned about 0.19% of Humacyte worth $602,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Endowment Wealth Management Inc. lifted its position in Humacyte by 5.1% during the 2nd quarter. Endowment Wealth Management Inc. now owns 109,458 shares of the company’s stock worth $229,000 after acquiring an additional 5,350 shares during the period. CWM LLC lifted its holdings in shares of Humacyte by 29,921.4% in the 2nd quarter. CWM LLC now owns 43,531 shares of the company’s stock valued at $91,000 after buying an additional 43,386 shares during the period. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Humacyte in the 2nd quarter valued at approximately $30,000. Concurrent Investment Advisors LLC lifted its holdings in shares of Humacyte by 17.5% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 51,115 shares of the company’s stock valued at $107,000 after buying an additional 7,615 shares during the period. Finally, Cyndeo Wealth Partners LLC acquired a new stake in shares of Humacyte in the 2nd quarter valued at approximately $42,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Laura E. Niklason sold 591,685 shares of Humacyte stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total value of $934,862.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Brady W. Dougan sold 591,685 shares of Humacyte stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total value of $934,862.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,482,090 shares of company stock valued at $7,466,382. Company insiders own 5.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on HUMA. Wall Street Zen cut Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, August 17th. TD Cowen reduced their price target on Humacyte from $5.00 to $3.50 and set a “buy” rating for the company in a report on Tuesday, August 12th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Monday, October 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a report on Wednesday, October 8th. Finally, UBS Group set a $6.00 price objective on Humacyte in a report on Monday, October 13th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.71.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $1.69 on Friday. The company has a market cap of $267.65 million, a P/E ratio of -3.76 and a beta of 1.89. The company has a quick ratio of 1.93, a current ratio of 2.45 and a debt-to-equity ratio of 2.97. Humacyte, Inc. has a 52 week low of $1.15 and a 52 week high of $6.77. The business has a fifty day simple moving average of $1.66 and a 200-day simple moving average of $1.94.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.94 million. Equities research analysts forecast that Humacyte, Inc. will post -1.27 EPS for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.